Achillion Pharmaceuticals, Inc. (ACHN) financial statements (2021 and earlier)

Company profile

Business Address 300 GEORGE STREET
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5030036445915312265
Cash and cash equivalents50437782743319
Short-term investments 257287378798847
Receivables1212100
Prepaid expense000000
Prepaid expense and other current assets2
Income taxes receivable0 
Other undisclosed current assets224217112 
Total current assets:27530438346315512568
Noncurrent Assets
Property, plant and equipment2332211
Long-term investments and receivables 3128  3612
Long-term investments 3128  3612
Restricted cash and investments0000000
Deferred costs    000
Other noncurrent assets0000  
Total noncurrent assets:23431223814
TOTAL ASSETS:27833841446515716282
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1213141414109
Accounts payable2574654
Accrued liabilities97710655
Employee-related liabilities    111
Debt0000000
Other undisclosed current liabilities    (1)(1)(1)
Total current liabilities:121314151399
Noncurrent Liabilities
Long-term debt and lease obligation 000000
Long-term debt, excluding current maturities 000000
Liabilities, other than long-term debt000    
Deferred revenue and credits00    
Deferred rent credit0
Total noncurrent liabilities:0000000
Total liabilities:121314151399
Stockholders' equity
Stockholders' equity attributable to parent26632539945014315372
Common stock0000000
Common stock, share subscribed but unissued, subscriptions receivable    (6)  
Additional paid in capital939927917905600535395
Accumulated other comprehensive income (loss)(0)(0)0(0)(0)00
Accumulated deficit(673)(603)(517)(456)(451)(382)(323)
Total stockholders' equity:26632539945014315372
TOTAL LIABILITIES AND EQUITY:27833841446515716282

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Gross profit:  1566  3
Operating expenses(76)(90)(80)(81)(69)(59)(50)
Operating loss:(76)(90)(65)(15)(69)(59)(47)
Nonoperating income (expense)
(Investment Income, Nonoperating)
643101(0)
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Loss from continuing operations before income taxes:(70)(85)(62)(14)(69)(59)(48)
Income tax expense    (30) (4)
Net loss:(70)(85)(62)(14)(99)(59)(51)
Other undisclosed net income attributable to parent   930 4
Net loss available to common stockholders, diluted:(70)(85)(62)(5)(69)(59)(47)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(70)(85)(62)(14)(99)(59)(51)
Other comprehensive income (loss)0(1)0(0)(0)(0)0
Comprehensive loss:(70)(86)(62)(14)(99)(59)(51)
Other undisclosed comprehensive income, net of tax, attributable to parent   930 4
Comprehensive loss, net of tax, attributable to parent:(70)(86)(62)(5)(69)(59)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: